SCHEMBL10798707

SCHEMBL10798707

CC1(C)OCCC(c2ccccc2)O1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
HCRTR2 O43614 4/20 0.38
HCRTR1 O43613 2/20 0.38
KDM1A O60341 4/20 0.37
MAOA P21397 4/20 0.37
MAOB P27338 4/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CYP3A4 P08684 1/20 0.34
MAPK1 P28482 1/20 0.34
TRPA1 O75762 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7088611 0.81 TSHR (0.45) TSHRMAOBSLC6A2SLC6A4SLC6A3
SCHEMBL5371551 0.81 TSHR (0.50) TSHRHCRTR2HCRTR1KDM1AMAOA
SCHEMBL7787343 0.81 TSHR (0.50) TSHRHCRTR2HCRTR1KDM1AMAOA
SCHEMBL16377614 0.81 TSHR (0.50) TSHRHCRTR2HCRTR1KDM1AMAOA
SCHEMBL9035063 0.80 CYP2A6 (0.48) CYP3A4TRPA1
SCHEMBL2943652 0.80 HCRTR1 (0.40) HCRTR2HCRTR1KDM1ASLC6A2SLC6A4
SCHEMBL2948970 0.79 KMO (0.48) HCRTR2HCRTR1KDM1AL3MBTL1
SCHEMBL22006623 0.78 TSHR (0.42) TSHRMAOBSLC6A2SLC6A4SLC6A3
SCHEMBL11507924 0.77 TSHR (0.38) TSHRKDM1AMAOAMAOBSLC6A2
SCHEMBL28642739 0.76 HTR2B (0.37) HCRTR2HCRTR1KDM1ASLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115666560-A Methods and pharmaceutical compositions for treating thromboxane A2 receptor antagonists of COVID-19 马丁·奥格特树 2023-01-31 CN disclosed
US-20210226253-A1 ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY MURATA MANUFACTURING CO., LTD. (JP) 2021-07-22 US disclosed
EP-0246195-A1 Optically active iridium complexes and their use CIBA-GEIGY AG (CH) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210226253-A1 ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY TPO, DNASE1, KCNN2 TSHR 1943/4885HCRTR2 2594/4885HCRTR1 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.